Headline News

 

Amgen announces new positive topline phase 3 results for subcutaneous Tepezza

Posted on April 07, 2026

Allergan Aesthetics announces all access CoolMonth with deals on coolsculpting

Posted on April 07, 2026

Wegovy highlighted greater weight loss than orforglipron and lower odds of stopping medication due to side effects in a new indirect comparison

Posted on April 06, 2026

Astrazeneca’s Efzimfotase alfa highlighted positive results from Phase III clinical programme in hypophosphatasia

Posted on April 06, 2026

AstraZeneca’s Imfinzi plus Imjudo combined with lenvatinib and TACE show significant improvement in progression-free survival in embolisation eligible unresectable liver cancer in EMERALD-3 Phase III trial

Posted on April 06, 2026

Rezurock approved to treat chronic graft vs host disease

Posted on April 06, 2026

Bristol Myers Squibb expands standing in the Gaap to advance care in multiple myeloma as program marks 10 Years

Posted on April 06, 2026

Lilly’s Foundayo approved as the only GLP-1 pill for weight loss that can be taken any time

Posted on April 06, 2026

Lilly set to acquire Centessa Pharmaceuticals to further advance treatments for sleep wake disorders

Posted on April 06, 2026

Denali Therapeutics announces approval of AVLAYAH for the treatment of hunter syndrome

Posted on March 30, 2026

Novo Nordisk’s triple agonist UBT251 highlighted a mean HbA1c reduction after 24 weeks in phase 2 trial in patients with type 2 diabetes

Posted on March 30, 2026

Novo Nordisk’s Awiqli approved as the first once weekly basal insulin treatment for adults with type 2 diabetes

Posted on March 30, 2026

GSK’s Bepirovirsen accepted for review as a potential first functional cure for chronic hepatitis B in China

Posted on March 30, 2026

Exdensur approved for the treatment of severe asthma in China

Posted on March 30, 2026

Lilly’s EBGLYSS reported up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis

Posted on March 30, 2026